文献速递胸部肿瘤放疗放疗物理与技术

局部晚期非小细胞肺癌中免疫细胞估计辐射剂量(EDRIC)的影响:多中心随机PET-Plan试验的二次分析

Impact of estimated dose of radiation to immune cells (EDRIC) in locally advanced Non-Small-Cell lung Cancer: A secondary analysis of the multicenter randomized PET-Plan trial.
PubMed 文献 · Radiother Oncol · 2025-04-25

该研究为PET-Plan随机试验的二次分析,纳入153例接受化放疗的局部晚期NSCLC患者,评估免疫细胞估计辐射剂量(EDRIC)对生存的影响。结果显示,原模型平均EDRIC为5.70 Gy,与PFS(HR=1.77)和OS(HR=1.72)呈强负相关;改良模型平均EDRIC为5.30 Gy,仅与PFS负相关。省略选择性淋巴结照射未影响EDRIC,平均体剂量(MBD)可能是EDRIC的主要贡献因素。

要点

  • 原模型平均EDRIC 5.70 Gy与PFS(HR=1.77)和OS(HR=1.72)呈强负相关。
  • 改良模型平均EDRIC 5.30 Gy与PFS负相关(HR=1.66),但与OS无显著相关(HR=1.40,p=0.122)。
  • 放疗分组(A vs B)和技术(3D-CRT vs IMRT)均未影响EDRIC(p=0.889和p=0.958)。

核心结论

  • 在PET-Plan试验的二次分析中,较高的免疫系统辐射剂量与更差的PFS相关。
  • 省略选择性淋巴结照射未影响EDRIC。
  • MBD可能足以作为EDRIC的替代指标,因其更易获得且所需计算更少。

研究设计与样本

  • 研究为前瞻性多中心随机PET-Plan试验(ARO-2009-09;NCT00697333)的二次分析。
  • 纳入既往接受化放疗至60-74 Gy的局部晚期NSCLC患者,放疗计划基于18F-FDG PET/CT。
  • A组靶向所有CT阳性淋巴结加50 Gy选择性淋巴结照射,B组仅靶向PET阳性淋巴结。
  • EDRIC采用Jin等原模型及队列特异性权重参数的改良评分计算。
  • 153例患者有足够数据,中位随访时间(95%CI)为41.6(34.6-53.7)个月。

主要发现

  • 原模型平均EDRIC(范围)为5.70(3.23-8.44)Gy,与PFS呈强负相关(HR=1.77;95%CI 1.23-2.54;p=0.002),与OS呈强负相关(HR=1.72;95%CI 1.12-2.65;p=0.01)。
  • 改良模型平均EDRIC(范围)为5.30(3.01-8.38)Gy,与PFS呈强负相关(HR=1.66;95%CI 1.16-2.38;p=0.006),但与OS无显著相关(HR=1.40;95%CI 0.91-2.15;p=0.122)。
  • 放疗分组(A组 vs B组)未影响EDRIC(p=0.889),技术(3D-CRT vs IMRT)未影响EDRIC(p=0.958)。
  • EDRIC未影响早期或延迟性血液学毒性发生率。
  • 多因素分析中,平均体剂量(MBD)是EDRIC方程对PFS和OS的主要贡献因素。

关键数值与推荐

  • 原模型平均EDRIC为5.70(3.23-8.44)Gy,与PFS的HR=1.77(95%CI 1.23-2.54;p=0.002),与OS的HR=1.72(95%CI 1.12-2.65;p=0.01)。
  • 改良模型平均EDRIC为5.30(3.01-8.38)Gy,与PFS的HR=1.66(95%CI 1.16-2.38;p=0.006),与OS的HR=1.40(95%CI 0.91-2.15;p=0.122)。
  • 放疗分组(A组 vs B组)对EDRIC影响p=0.889,技术(3D-CRT vs IMRT)对EDRIC影响p=0.958。

临床怎么用

  • 在局部晚期NSCLC的化放疗中,考虑免疫系统作为放疗危及器官具有重要意义,尤其在巩固免疫治疗时代。
  • MBD可能作为EDRIC的替代指标用于临床,因其更易获得且所需计算更少。
  • 未来试验应旨在完善现有模型并研究降低EDRIC的方法,以限制其对接受化放疗的局部晚期NSCLC患者的影响。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A higher estimated dose of radiation to immune cells (EDRIC) has been proposed as an explanation for failed attempts at thoracic radiation intensification as a part of concurrent chemoradiotherapy (cCRT) for locally advanced non-small-cell lung cancer (NSCLC), as lymphopenia in particular is a negative prognostic factor in this context. We studied the impact of EDRIC on survival in this secondary analysis of the prospective PET-Plan trial (ARO-2009-09; NCT00697333). Considering the immune system as an organ at risk for radiotherapy is of major importance in the current era of consolidation immunotherapy. METHODS: Eligible patients had previously received chemoradiotherapy up to 60-74 Gy with radiation treatment planning based on an 18F-FDG PET/CT targeting all CT positive lymph nodes plus 50 Gy elective nodal irradiation (arm A) versus targeting only PET-positive nodes (arm B). EDRIC was calculated with the original model by Jin et al. in addition to a modified score with cohort-specific weight parameters. RESULTS: Sufficient data were available in 153 patients with a median follow-up time (95 % confidence interval [CI]) of 41.6 (34.6 - 53.7) months. Using the original model, the mean EDRIC (range) was 5.70 (3.23 - 8.44) Gy and showed a strong inverse correlation with PFS (hazard ratio [HR] = 1.77; 95 % CI 1.23-2.54; p = 0.002) and OS (HR = 1.72; 95 % CI 1.12-2.65; p = 0.01). The mean modified EDRIC (range) was 5.30 (3.01 - 8.38) Gy, again with a strong inverse correlation with PFS (HR = 1.66; 95 % CI 1.16-2.38; p = 0.006) but not OS (HR = 1.40; 95 % CI 0.91-2.15; p = 0.122). Neither radiation treatment allocation (arm A vs. B) nor technique (3D-CRT vs. IMRT) influenced EDRIC (p = 0.889 and p = 0.958, respectively) and EDRIC did not influence the rate of early or delayed hematological toxicity. On multivariate analysis, mean body dose (MBD) was the main contributing factor of the EDRIC equation to PFS and OS. CONCLUSION: Higher doses of radiation to the immune system were associated with worse PFS in this secondary analysis of the PET-Plan trial. The omission of elective nodal irradiation did not influence EDRIC. MBD could potentially suffice as a surrogate for EDRIC, as it is more readily available and requires fewer calculations. Future trials should aim to refine existing models and investigate ways to reduce EDRIC to limit its effects in patients undergoing cCRT for locally advanced NSCLC.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Dejonckheere CS, Nour Y, Sahlmann J, et al. Impact of estimated dose of radiation to immune cells (EDRIC) in locally advanced Non-Small-Cell lung Cancer: A secondary analysis of the multicenter randomized PET-Plan trial. Radiother Oncol. 2025. PMID: 40288687. doi:10.1016/j.radonc.2025.110907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。